{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:46:20Z","timestamp":1792082780069,"version":"4.4.0"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) such as anti-programmed death-1 (PD-1) and its ligand PD-L1 and anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibodies, are involved in T cell-mediated immune response augmentation and promote anti-tumor immunity. Cancer patients treated with combination of immunotherapy, chemotherapy, radiotherapy, and targeted therapy exhibit superior clinical outcomes and tolerance compared with patients treated with monotherapies. However, immutherapy is associated with several concomitant immune-related adverse events (irAEs). For instance, IrAEs interferes with function of gastrointestinal tract, endocrine, dermatological, nervous system and musculoskeletal systems. ICIs-associated pancreatic injury might causes decrease in endocrine and exocrine pancreatic function, resulting in metabolic and nutritional disorders. Clinicians who administer immune checkpoint inhibitors to cancer patients are diagnosed with hyperglycemia, abdominal pain and steatorrhea. Currently, the precise mechanism of ICIs-associated pancreatic injury has not been fully explored. This paper summarizes incidence, diagnosis, clinical characteristics, potential mechanisms, and treatment management patterns of ICIs-associated pancreatic AEs based on previous studies. In addition, possible management approaches of these adverse effects are presented in this paper. in the findings summarized in this paper lay a basis for management of ICIs-associated pancreatic AEs and expanding future immunotherapy applications.<\/jats:p>","DOI":"10.3389\/fonc.2021.627612","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T08:45:34Z","timestamp":1614242734000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":58,"title":["Immunotherapy-Associated Pancreatic Adverse Events: Current Understanding of Their Mechanism, Diagnosis, and Management"],"prefix":"10.3389","volume":"11","author":[{"given":"Ya","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weichun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kezhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xubao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-017-0480-y","article-title":"Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature","volume":"12","author":"Hickmott","year":"2017","journal-title":"Targeted Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"J Exp Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40425-017-0303-9","article-title":"Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma","volume":"5","author":"Changizzadeh","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0002","article-title":"Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2178-0","article-title":"Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and\/or anti-CTLA-4) for metastatic melanoma: a retrospective study","volume":"67","author":"Gauci","year":"2018","journal-title":"Cancer Immunol Immunother: CII"},{"key":"B7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13256-020-02502-w","article-title":"Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report","volume":"14","author":"Porntharukchareon","year":"2020","journal-title":"J Med Case Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2101-4","article-title":"Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma","volume":"105","author":"Munakata","year":"2017","journal-title":"Int J Hematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e8395","DOI":"10.7759\/cureus.8395","article-title":"A Tale of Immune-Related Adverse Events With Sequential Trials of Checkpoint Inhibitors in a Patient With Metastatic Renal Cell Carcinoma","volume":"12","author":"Singh","year":"2020","journal-title":"Cureus"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02076","article-title":"Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression","volume":"11","author":"Wen","year":"2020","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13424","article-title":"Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes","volume":"200","author":"Quandt","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr3750","article-title":"Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-lymphocyte-associated Protein-4 Inhibitors): Results of a Retrospective Study","volume":"11","author":"Bajwa","year":"2019","journal-title":"J Clin Med Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1530\/edm-19-0152","article-title":"Pembrolizumab-induced fulminant type 1 diabetes with C-peptide persistence at first referral","volume":"2020","author":"Kusuki","year":"2020","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219841116","article-title":"Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event","volume":"26","author":"Yilmaz","year":"2020","journal-title":"J Oncol Pharm Pract: Off Publ Int Soc Oncol Pharm Practition"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02221","article-title":"Acquired Lipodystrophy Associated With Nivolumab in a Patient With Advanced Renal Cell Carcinoma","volume":"104","author":"Falcao","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e000591","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1530\/edm-18-0153","article-title":"A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma","volume":"2019","author":"Hakami","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/edm-19-0045","article-title":"Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment","volume":"2019","author":"Meng\u00edbar","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1507\/endocrj.EJ18-0328","article-title":"Fulminant type 1 diabetes associated with Isolated ACTH deficiency induced by anti-programmed cell death 1 antibody-insight into the pathogenesis of autoimmune endocrinopathy","volume":"66","author":"Okahata","year":"2019","journal-title":"Endocr J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3747\/co.26.4130","article-title":"A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma","volume":"26","author":"Sakaguchi","year":"2019","journal-title":"Curr Oncol (Toronto Ont)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13022","article-title":"Case of fulminant type\u00a01 diabetes induced by the anti-programmed death-ligand\u00a01 antibody, avelumab","volume":"10","author":"Shibayama","year":"2019","journal-title":"J Diabetes Invest"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-2243","article-title":"Anti-Programmed Death 1 (PD-1) Antibodies and the Pancreas: A Diabetic Storm Ahead","volume":"41","author":"Marchand","year":"2018","journal-title":"Diabetes Care"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e12907","DOI":"10.1097\/md.0000000000012907","article-title":"Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report","volume":"97","author":"Li","year":"2018","journal-title":"Medicine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.09.014","article-title":"Autoimmune pancreatitis after nivolumab anti-programmed death receptor-1 treatment","volume":"104","author":"Dehghani","year":"2018","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2203-3","article-title":"Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC","volume":"67","author":"Matsuura","year":"2018","journal-title":"Cancer Immunol Immunother: CII"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1530\/edm-17-0174","article-title":"New-onset insulin-dependent diabetes due to nivolumab","volume":"2018","author":"Zaied","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9518-17","article-title":"Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody","volume":"57","author":"Shiba","year":"2018","journal-title":"Internal Med (Tokyo Japan)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/cmr.0000000000000418","article-title":"Fulminant type 1 diabetes associated with nivolumab in a patient with metastatic melanoma","volume":"28","author":"Takahashi","year":"2018","journal-title":"Melanoma Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1620\/tjem.244.33","article-title":"Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab","volume":"244","author":"Sakurai","year":"2018","journal-title":"Tohoku J Exp Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-220999","article-title":"New-onset diabetes after nivolumab treatment","volume":"2018","author":"Capitao","year":"2018","journal-title":"BMJ Case Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12627","article-title":"Acute-onset type 1 diabetes mellitus caused by nivolumab in a patient with advanced pulmonary adenocarcinoma","volume":"8","author":"Kumagai","year":"2017","journal-title":"J Diabetes Invest"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0245-2","article-title":"Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer","volume":"5","author":"Godwin","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00262-016-1913-7","article-title":"A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes","volume":"66","author":"Chae","year":"2017","journal-title":"Cancer Immunol Immunother: CII"},{"key":"B34","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1159\/000480634","article-title":"Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management","volume":"10","author":"Kapke","year":"2017","journal-title":"Case Rep Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13486","article-title":"Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient","volume":"44","author":"Teramoto","year":"2017","journal-title":"J Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2016.2923","article-title":"A case of fulminant type 1 diabetes mellitus, with a precipitous decrease in pancreatic volume, induced by nivolumab for malignant melanoma: analysis of HLA and CTLA-4 polymorphisms","volume":"27","author":"Ishikawa","year":"2017","journal-title":"Eur J Dermatol: EJD"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.12.015","article-title":"Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by\u00a0Nivolumab in Patients with Non-Small Cell Lung\u00a0Cancer","volume":"12","author":"Usui","year":"2017","journal-title":"J Thoracic Oncol: Off Publ Int Assoc Study Lung Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.endinu.2017.01.005","article-title":"Fulminant type 1 diabetes mellitus associated with pembrolizumab","volume":"64","author":"Mizab Mellah","year":"2017","journal-title":"Endocrinol Diabetes Y Nutricion"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000173","article-title":"Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer","volume":"40","author":"Leonardi","year":"2017","journal-title":"J Immunother (Hagerstown Md: 1997)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12531","article-title":"Fulminant type\u00a01 diabetes mellitus with anti-programmed cell death-1 therapy","volume":"7","author":"Okamoto","year":"2016","journal-title":"J Diabetes Invest"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.239.155","article-title":"Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes","volume":"239","author":"Miyoshi","year":"2016","journal-title":"Tohoku J Exp Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1835-4","article-title":"A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management, and outcome","volume":"65","author":"Hansen","year":"2016","journal-title":"Cancer Immunol Immunother: CII"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-217454","article-title":"Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma","volume":"2016","author":"Aleksova","year":"2016","journal-title":"BMJ Case Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.14310\/horm.2002.1656","article-title":"A case of multiple immune toxicities from Ipilimumab and pembrolizumab treatment","volume":"15","author":"Humayun","year":"2016","journal-title":"Hormones (Athens Greece)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1689-1","article-title":"Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report","volume":"64","author":"Martin-Liberal","year":"2015","journal-title":"Cancer Immunol Immunother: CII"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"38","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0889","article-title":"Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes","volume":"38","author":"Mellati","year":"2015","journal-title":"Diabetes Care"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1331","article-title":"Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes","volume":"38","author":"Gaudy","year":"2015","journal-title":"Diabetes Care"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20022125","article-title":"The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice","volume":"198","author":"Ansari","year":"2003","journal-title":"J Exp Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e89561","DOI":"10.1371\/journal.pone.0089561","article-title":"Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes","volume":"9","author":"Kochupurakkal","year":"2014","journal-title":"PloS One"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2337\/db09-1135","article-title":"Deficiency in B7-H1 (PD-L1)\/PD-1 coinhibition triggers pancreatic beta-cell destruction by insulin-specific, murine CD8 T-cells","volume":"59","author":"Rajasalu","year":"2010","journal-title":"Diabetes"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0806","article-title":"Cases from the Immune-Related Adverse Event Tumor Board: Diagnosis and Management of Immune Checkpoint Blockade Induced Diabetes","volume":"25","author":"Zagouras","year":"2020","journal-title":"Oncologist"},{"key":"B54","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-019-01402-w","article-title":"The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors","volume":"56","author":"Marchand","year":"2019","journal-title":"Acta Diabetol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18124","article-title":"Acquired generalized lipodystrophy under immune checkpoint inhibition","volume":"182","author":"Haddad","year":"2020","journal-title":"Br J Dermatol"},{"key":"B57","volume-title":"Common terminology criteria for adverse events (CTCAE) version 5.0","year":"2017"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2019.04.015","article-title":"Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis","volume":"19","author":"George","year":"2019","journal-title":"Pancreatology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000202","article-title":"Significance of Immune-related Lipase Increase Induced by Antiprogrammed Death-1 or Death Ligand-1 Antibodies: A Brief Communication","volume":"41","author":"Michot","year":"2018","journal-title":"J Immunother (Hagerstown Md 1997)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw260","article-title":"Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab","volume":"109","author":"Friedman","year":"2017","journal-title":"J Natl Cancer Institute"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_100013","article-title":"Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management","volume":"38","author":"Grover","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-019-01935-2","article-title":"Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor","volume":"44","author":"Alessandrino","year":"2019","journal-title":"Abdom Radiol (NY)"},{"key":"B63","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11523-019-00694-w","article-title":"Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Imaging Findings and Literature Review","volume":"15","author":"Porcu","year":"2020","journal-title":"Targeted Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1097\/cmr.0000000000000611","article-title":"Immune-related pancreatitis associated with checkpoint blockade in melanoma","volume":"29","author":"Kohlmann","year":"2019","journal-title":"Melanoma Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2518","article-title":"T-Lymphocyte Infiltration to Islets in the Pancreas of a Patient Who Developed Type 1 Diabetes After Administration of Immune Checkpoint Inhibitors","volume":"42","author":"Yoneda","year":"2019","journal-title":"Diabetes Care"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0642-y","article-title":"Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases","volume":"58","author":"Di Giacomo","year":"2009","journal-title":"Cancer Immunol Immunother: CII"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0126","article-title":"Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy","volume":"10","author":"Prasanna","year":"2018","journal-title":"Immunotherapy"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1465","article-title":"Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes","volume":"41","author":"Wright","year":"2018","journal-title":"Diabetes Care"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3366","article-title":"Diabetes mellitus induced by immune checkpoint inhibitors","author":"Zheng","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12700","article-title":"Latent autoimmune diabetes of the adult: current knowledge and uncertainty","volume":"32","author":"Laugesen","year":"2015","journal-title":"Diabetes Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events","volume":"21","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2016","journal-title":"Oncologist"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0012","article-title":"27 NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Cancer Netw: JNCCN"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1136\/gut.39.4.580","article-title":"Faecal elastase 1: a novel, highly sensitive, and specific tubeless pancreatic function test","volume":"39","author":"L\u00f6ser","year":"1996","journal-title":"Gut"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.627612\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T08:45:36Z","timestamp":1614242736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.627612\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":74,"alternative-id":["10.3389\/fonc.2021.627612"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.627612","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]},"article-number":"627612"}}